Target intelligence / Profile preview

Other cellular RNAs with partial complementarity to the anti-miR-7 sequence

Molecular classification
RNA, Messenger RNA, Non-coding RNA
01

Overview

Other cellular RNAs with partial complementarity to the anti-miR-7 sequence refers to the collection of endogenous transcripts that may inadvertently interact with antisense oligonucleotides (ASOs) or antagomirs designed to inhibit microRNA-7 (miR-7). miR-7 is a critical regulator of various oncogenic pathways, including the EGFR and PI3K/AKT signaling cascades, making it a significant target in oncology research (Horsham et al., 2015, PMID: 25613355). When anti-miR-7 agents are administered, they are intended to bind specifically to the miR-7 sequence; however, the short nature of these sequences allows for potential hybridization with other cellular RNAs that share partial complementarity (Bennett & Swayze, 2010, PMID: 20143915). These off-target interactions can lead to the unintended degradation of messenger RNAs (mRNAs) or the inhibition of their translation, which may result in cellular toxicity or adverse clinical effects (Lindow & Kauppinen, 2012, PMID: 22713471). In the context of drug development, these RNAs represent a major safety hurdle, as they can cause off-target silencing of genes unrelated to the disease pathology (Jackson & Linsley, 2010, PMID: 20844550). Consequently, identifying and minimizing binding to these non-target RNAs is essential for the design of safe and effective miRNA-based therapeutics. This group of RNAs is not a therapeutic target but rather a source of potential side effects and experimental noise in miR-7 inhibition studies.

Other names
Off-target RNAsNon-specific hybridization targetsAnti-miR-7 off-targetsHybridization-dependent off-targets
02

Mechanism of action

Unintended hybridization of antisense oligonucleotides to transcripts with partial sequence complementarity, leading to potential degradation or translational inhibition of non-target mRNAs (Bennett & Swayze, 2010).

03

Biological functions

Regulation of gene expression
04

Disease associations

CancerNeurodegenerative diseaseOff-target toxicity
05

Safety considerations

Off-target gene silencingCellular toxicityUnintended phenotypic changesHepatotoxicityNephrotoxicity
06

Interacting drugs

Anti-miR-7 oligonucleotides

2 more in the full profile.

Beyond the preview

Go deeper on Other cellular RNAs with partial complementarity to the anti-miR-7 sequence.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Other cellular RNAs with partial complementarity to the anti-miR-7 sequence.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call